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Introduction
It is estimated that ischemic heart disease will be the number one cause of 
disability and death worldwide by the year 2020[1]. Almost all cases result from 
coronary thrombosis following the erosion or rupture of an atherosclerotic le-
sion[2]. With the occlusion of the coronary blood flow ST segment elevation 
occurs on the electro cardiogram (ECG) and impaired myocardial perfusion 
causes ischemia that may result in myocardial cell death or injury, cardiac ar-
rhythmias, and ventricular dysfunction. Within 15 minutes of occlusion myo-
cardial cell death begins and rapidly proceeds from the endocardium to the 
epicardium in a wave front. Partial Salvage of the myocardium can be achieved 
by restoration of the blood flow within 3 to 6 hours, with the degree of salvage 
and the duration of ischemia being inversely proportional[3].
 The increasing sensitivity of cardiac biomarkers means that clinicians 
can detect lower levels of injury, but this does not provide information on the 
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Abstract
Background: ST-segment elevation myocardial infarction (STEMI) patients treated with primary percutaneous inter-
vention (PPCI) are at a high risk of death and MACE (Major Adverse Cardiovascular Events). One method to stratify 
these patients’ risk could be high-sensitivity cardiac troponin-T (hs-cTnT). Unfortunately; data using this approach is 
limited. The aim of this study was to investigate whether there is a correlation between initial levels of cTnT in STEMI 
patients with MACE. 
Methods: Initial hs-cTnT levels were measured in 167 patients with STEMI undergoing PPCI. Patients were divided 
into 2 groups: group A hs-cTnT below the median (83 patients); group B hs-cTnT above the median (84 patients). Pa-
tients were followed up for 2 years investigating mortality and MACE. 
Results: The median value of initial hs-cTnT was 100 ng / L. The mean hs-cTnT was 52 ± 26 ng / L in group A and 548 
± 458 ng / L in group B. 18 (10.8%) patients died during follow-up:13 (15.5%) in group B compared to only 5 (6%) in-
group A (P < 0.05). Further analysis showed that non-surviving patients were older, more likely to be female, had more 
diabetes mellitus, more hypertension, and more diffuse coronary artery disease. They also had worse outcomes such as 
heart failure, increased rates of recurrent chest pain, readmissions and other infrequent complications such as complete 
heart block, renal impairment, reinfarction, stent thrombosis, and upper gastrointestinal tract bleeding.
Conclusions: Increased initial hs-cTnT levels are associated with a higher risk of mortality and morbidity at 2-year 
follow up in patients from Erbil with STEMI undergoing PPCI.
 Keywords: hs-cTnT; STEMI; PPCI; Mortality; Morbidity
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cause of the damage[4]. The cardiac biomarker of choice to detect 
myocardial injury is cardiac troponin. Following cardiomyocyte 
injury, the initial release of cTnT is from the cytosolic pool, (6 – 
8% of cTnT dissolved in the cytosol). This is later followed by 
the release of myofilament bound protein[5]. The cornerstone of 
the diagnostic criteria for myocardial infarction (MI) is detec-
tion of a rise and fall in cTnT or cTnI[6], which occurs approx-
imately 3 hours after the onset of chest pain by conventional 
assays (non–high-sensitivity)[7]. cTnT continues to be released 
from necrotic cardiomyocytes as the contractile apparatus de-
generates. This causes persistent elevations of up to 10-14 days 
in cTnT after MI[8], which can be helpful for late diagnosis of 
MI. Successful recanalization of the infarct-related artery also 
induces a rapid release of cardiac troponins, which may indi-
cate reperfusion. With high-sensitivity assays (hs-cTn) there is 
more precise measurement of very low concentrations of cardiac 
troponin leading to assays which are capable of detecting cTnT 
in more than 50% of the healthy population[5,6, 9]. Ndrepepa et 
al.,[10] divided circulating hs-cTnT into 4 fractions according to 
the time of measurement in patients with ST segment elevation 
myocardial infarction (STEMI) who were undergoing primary 
percutaneous coronary intervention (PPCI). The first fraction is 
caused by physiological cardiomyocyte turnover[11]. The second 
fraction is due to enhanced cardiomyocyte stress by many abnor-
mal stimuli which cause leakage of troponin through multiple 
mechanisms[12]. The third fraction is from acute myocardial isch-
emia/necrosis in patients presenting with an acute coronary syn-
drome (ACS). For example in the early phase of STEMI where 
detection of troponin I correlates closely with infarct size[13] and 
mortality[14]. The fourth fraction relates to PPCI complications 
and correlates with a poor outcome[15]. The aim of this study was 
to determine if hs-cTnT measurements performed during initial 
admission to hospital of patients with STEMI about to undergo 




The study was approved by the local ethical committee of the 
Kurdistan Board of Medical Specialties. All patients involved in 
the study gave written informed consent. 
Patients
This study was a prospective review of patients with STEMI who 
were admitted to the surgical specialty hospital / cardiac center 
in Erbil city (Iraq) from January 2017 to June 2017 and who later 
underwent successful PPCI. This included cases referred from 
other hospitals. Patients were admitted to the coronary care unit 
(CCU), where they immediately had a standard 12 lead ECG 
taken. The criteria used for ST elevation was based on criteria 
from The European Society of Cardiology, American College of 
Cardiology, American Heart Association, and the World Heart 
Federation. Thus, new ST elevation at the J point in two contigu-
ous leads with the following cut off points: ≥ 0.1 mV in all leads 
(except V2-V3), in leads V2-V3 the following cut points apply: 
≥ 0.2 mV in men ≥ 40 years, ≥ 0.25 mV in men < 40 years, And 
≥ 0.15 mV in women[16]. Using this criteria 225 patients were en-
rolled in this study to be followed up for 2 years. Unfortunately 
contact was lost with 58 patients during follow up. Patients were 
excluded if they had been diagnosed with chronic renal failure, 
presented with cardiogenic shock or pulmonary odema, or un-
derwent emergency coronary artery bypass graft. Patients were 
also excluded if they had a severe comorbidity such as chronic 
obstructive pulmonary disease, liver or neurological diseases.
Procedures
After obtaining informed consent from patients or their rela-
tives, a detailed history and clinical examination were collected 
for every patient within the first 24 hours of their admission to 
the CCU. This mainly concentrated on clinical presentation and 
the arrival time of the patient to the CCU from the start of the 
symptoms. In addition, risk factors such as hypertension, diabe-
tes mellitus, smoking, hyperlipidemia, previous ischemic heart 
disease, and a positive family history were noted. ECG changes 
were used to locate the site of the MI depending on the presence 
of ST elevation and / or hyperacute T waves and development 
of Q waves in certain leads. All medications administered to the 
patient were recorded including antiplatelet, anticoagulation 
and thrombolytic therapy. A peripheral venous blood sample 
was taken at initial admission for hs-cTnT, creatine kinase-mus-
cle-brain band, complete blood picture, erythrocyte sedimenta-
tion rate, blood sugar, blood urea, serum creatinine and lipid pro-
file. The plasma concentration of cTnT was measured using the 
high sensitivity assay by a Cobas e411 immunoanalyzer based 
on electrochemiliuminescence technology (Roche Diagnostics) 
with the assay performed according to the manufacturer’s in-
structions (detection limit of 5 ng / L, 99th percentile in the gen-
eral population of 14 ng / L and 10% coefficient of variation 
level of 13 ng /L).
 Interventions were performed according to global and 
local guidelines (STEMI within first 24 hours, or persistent chest 
pain or heart failure within 48 hours), and the decision for PPCI 
was made by the interventional cardiologist on duty. All patients 
underwent PPCI with an oral loading dose of 180 mg of ticagre-
lor plus aspirin 300mg at time of admission. During the proce-
dure, intravenous heparin was administered; the use of glyco-
protein IIb / IIIa inhibitors was at the discretion of the operator, 
drug-eluting stents were used for PPCI. After the intervention, 
all patients were prescribed 100 mg / day of aspirin indefinitely, 
ticagrelor 90 mg twice per day for 12 months, and other cardiac 
medications at the discretion of the patient’s physician. Within 
1-2 days of admission a doppler echocardiography was arranged 
for most patients.
Endpoints
Patients were followed up for up to 20 to 24 months (median 
22 months) after STEMI. The primary endpoint of interest in 
this study was all-cause mortality. The secondary endpoint was 
other MACE including heart failure, reinfarction, readmission, 
and the need for further revascularization. Information on deaths 
was obtained from hospital records or telephone contact with 
relatives of the patient. Arterial hypertension was diagnosed in 
the presence of active treatment with antihypertensive agents or 
otherwise as a systolic blood pressure of   ≥ 140 mm Hg and / or 
diastolic blood pressure of   ≥ 90 mm Hg on at least 2 separate 
occasions[17]. Diabetes mellitus was diagnosed in the presence 
of active treatment with antidiabetic agents or based on current 
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guidelines[18]. Heart failure was diagnosed according to modified 
Framingham clinical criteria for the diagnosis of heart failure[19]. 
The infarct related artery is the coronary artery containing the 
culprit lesion which presented as an acute occlusion, intraluminal 
filling defect or thrombus, ulcerated plaque with contrast-filled 
pocket protruding into the plaque with or without delayed con-
trast wash-out, dissection, extraluminal contrast, or intraluminal 
flaps[20,21]. PPCI success was defined as TIMI III flow across the 
culprit lesion and less than 30% residual stenosis[22]. 
Data Analysis
According to initial admission hs-cTnT levels patients were di-
vided into two groups: first group less than the median value 
(group A) and second group more than the median (group B). A 
further analysis was carried out according to the survival status 
of the patients. The computer software SPSS v.25 for windows 
was used to analyze the data. Chi2 test was used for categori-
cal variables to determine the significance of any difference for 
any observed feature between the two groups. Continuous data 
is expressed as mean ± SD. A p value < 0.05 was considered 
significant.
Results
A total of 167 patients were included in this study. The median 
value of initial hs-cTnT was 100 ng / L. Using this value the pa-
tients were divided into 2 groups. Group A (83 patients) patients 
with hs-cTnT measurements below the median, range 14-98 ng 
/ L, mean 52 ± 26 ng / L. Group B (84 patients) patients had 
hs-cTnT measurements above the median, range 100-1890 ng 
/ L, mean 548 ± 458 ng / L. The distribution chart of patients 
according to their levels of serum hs-cTnTis shown in figure 1.
Figure 1: distribution of patients according to hs-cTnT levels. Patients 
are ranked in order of ascending hs-cTnT levels.
Overall, patient ages ranged from 29-87 years with a mean 
of 57.5 ± 11.1 years and there were more males than females. 
These and other baseline characteristics compared between the 2 
groups are shown in table 1. There was no significant differences 
in age categories, gender, incidence of hypertension, smoking 
status, infarct related artery and number of vessels affected be-
tween the 2 groups. However, proportionately more patients in 
group B had diabetes mellitus.
Table 1: clinical characteristics of patients.Baseline clinical character-
istics of the patients grouped according to whether their initial hs-cTnT 
was above (group A) or below (group B) the median. HTN: hyperten-
sion; DM: diabetes mellitus; LAD: left anterior descending; RCA: right 
coronary artery; LCX: left circumflex.
Group A Group B Total p value




20-39 6(7.2%) 6(7.1%) 12(7.2%) 0.405
40-59 42(50.6%) 33(39.3%) 75(44.9%)
60-79 34(41%) 42(50%) 76(45.5%)
80-90 1(1.2%) 3(3.6%) 4(2.4%)
Gender Female 17(20.5%) 21(25%) 38(22.8%) 0.486
Male 66(79.5%) 63(75%) 129(77.2%)
DM 16(19.3%) 37(44%) 53(31.7%) 0.001
HTN 29(34.9%) 35(41.7%) 64(38.3%) 0.371
Current 
Smoker




LAD 44(53%) 48(57.1%) 92(55.1%) 0.410
RCA 32(38.6%) 33(39.3%) 65(38.9%)
LCX 7(8.4%) 3(3.6%) 10(6.0%)





S ing l e 
vessel
31(37.3%) 24(28.6%) 55(32.9%) 0.475
T w o 
vessels
26(31.3%) 31(36.9%) 57(34.1%)




Table 2: Survival status in both groups. The number of living and dead 
patients grouped according to whether their hs-cTnT was above or be-
low the median.
Group A Group B Total
Survival
Live 78(94%) 71(84.5%) 149(89.2%)
Dead 5(6%) 13(15.5%) 18(10.8%)
Total patients 83(100%) 84(100%) 167(100%)
P.value : 0.042
A total of 18(10.8%) patients died during follow-up (table 2). 
Significantly more of these patients came from group B (13, 
15.5%) compared to those in group A (5, 6%). With respect to 
the occurrence of other complications in the 2 groups, there were 
no significant differences (table 3). 
Table 3: follow up outcomes. The incidence of complications grouped 
according to whether the initial hs-cTnT was above or below the medi-
an. PCI: percutaneous coronary intervention.
Group A Group B Total p value
Heart Failure 12(14.5%) 14(16.7%) 26(15.6%) 0.429
Second PCI 16(19.3%) 15(17.9%) 31(18.6%) 0.485
Re-admission 11(13.3%) 9(10.7%) 20(12.0%) 0.395
Recurrent Chest 
pain
12(14.5%) 15(17.9%) 27(16.2%) 0.350
Other complica-
tions
8(9.6%) 10(11.9%) 18(10.8%) 0.412
This included other complications comprising stent thrombosis, 
renal failure, stroke and upper gastrointestinal tract bleeding. 
 In order to investigate whether there were any defining 
ST-Elevation Myocardial Infarction in Erbil City, Iraq
Ameen H.M.H., et al. Vol 4:1 pp 37
characteristics in the patients who died, a further analysis was 
carried out comparing the survived versus non survived groups. 
Table 4 shows the baseline clinical characteristics of patients in 
these 2 groups. Patients in the non survived group were older, 
more likely to be female, had more diabetes mellitus, more hy-
pertension and a greater number of affected vessels. Smoking 
and infarct related artery were not significantly different be-
tween the two groups.
Table 4: clinical characteristics of patients according to survival status. 
The baseline clinical characteristics of all patients grouped according to 






2 0 - 3 9 
year
11(7.4%) 1(5.6%) 12(7.2%) <0.001
4 0 - 5 9 
year
74(49.7%) 1(5.6%) 75(44.9%)
60-79 63(42.3%) 13(72.2%) 76(45.5%)
80-90 1(0.7%) 3(16.7%) 4(2.4%)
Gender
Female 30(20.1%) 8(44.4%) 38(22.8%) 0.020
Male 119(79.9%) 10(55.6%) 129(77.2%)
DM 40(26.8%) 13(72.2%) 53(31.7%) <0.001
HTN 53(35.6%) 11(61.1%) 64(38.3%) 0.035
Current 
Smoker




LAD 83(55.7%) 9(50%) 92(55.1%) 0.379
RCA 56(37.6%) 9(50%) 65(38.9%)






55(36.9%) 0(0.0%) 55(32.9%) 0.005
T w o 
vessels
49(32.9%) 8(44.4%) 57(34.1%)




 At the follow up point the non survived group had more 
heart failure, more re-admissions, more recurrent chest pain and 
more of the other complications including complete heart block, 
renal impairment, reinfarction, stent thrombosis, and upper gas-
trointestinal tract bleeding compared to the survived group (ta-
ble 5). There was no difference in the need for revascularization 
between the 2 groups.
Table 5: follow up outcomes in both groups according to survival sta-
tus. The incidence of complications in patients grouped according to 




Heart Failure 17(11.4%) 9(50%) 26(15.6%) < 0.001
Second PCI 30(20.1%) 1(5.6%) 31(18.6%) 0.133
Re-admission 13(8.7%) 7(38.9%) 20(12%) <0.001
Recurrent Chest pain 19(12.8%) 8(44.4%) 27(16.2%) <0.001
Other complications 9 (6%) 9(50%) 18(10.8%) <0.001
Discussion
There are only a few studies that have assessed the prognostic 
value of cardiac troponins in patients with STEMI undergoing 
PPCI. Both admission and peak post-procedural values provide 
information on prognosis that can be incorporated into risk pre-
diction scores. The advantages of using admission values is that 
these correlate more with the extent of spontaneous ischemic 
damage and are not subject to the interferences caused by the 
PPCI procedure or other treatment applied in the early stages of 
STEMI. Thus admission values can be preferred for inclusion in 
risk prediction scores[10].  
 This study demonstrates that patients with STEMI un-
dergoing PPCI who have higher admission hs-cTnT levels had 
a higher risk of 2-year all-cause mortality. Although all patients 
presented early (within the first few hours of starting chest pain), 
which is reflected in the level of hs-cTnT, the more hs-cTnT the 
more time lapsed from symptoms, the more necrosis occurs, 
the more extensive and established the ischemic outcome. This 
study also observed that the non-survived group have higher lev-
els of hs-cTnT than the survived group and were mostly older in 
age. This agrees with Ndrepepa et al.[10] who studied 818 patients 
with STEMI, treated by PPCI,with a 3 year follow up, who also 
found that the nonsurvivors were older in age and more likely to 
have type 2 diabetes, higher preprocedural and peak postproce-
dural hs-cTnT levels, lower estimated glomerular filtration rate 
and left ventricular function, but less likely to have a history of 
arterial hypertension or hypercholesterolemia. They concluded 
that admission or peak post procedural hs-cTnT is independently 
associated with higher 3 year mortality[10].
 In the current study females have a greater risk of de-
veloping complications of MI,which is similar to Wijnbergen et 
al[22]. They found that mortality was higher and there was worse 
long term outcome after PPCI for STEMI in females. In addi-
tion, De Luca[23] studied 1548 patients of which 353 were wom-
en (22.8%) and showed that females tended to be more advanced 
in age, had higher prevalence of hypertension, diabetes, longer 
ischemia time, higher Killip class, smaller vessel caliber, and 
significantly higher 1-year mortality rate at univariate but not at 
multivariate analysis. This is also confirmed by van der Meer et 
al.,[24] in a systematic review of prognostic studies which showed 
a worse outcome in women with STEMI leading to the conclu-
sion that mortality is higher in women with STEMI and can be 
explained by their unfavorable risk profile and longer symptom‐
to‐ balloon time.
 The current study observed that diabetic patients have 
higher levels of troponin on admission and higher mortality on 
follow up. Piccolo et al.,[25] conclude that diabetes in the ACS 
setting confers a worse prognosis with 1-year mortality >10% in 
both STEMI and non ST-elevation acute coronary syndrome[26]. 
also confirms that even with reperfusion, patients with STEMI 
and DM have greater long term mortality than do patients with-
out DM.
 In the baseline patient characteristics of Ndrepepa et 
al[10]., the number of current smokers was significantly lower 
in the non-survived group (15.6%) than in the survived group 
(38%). In this study also a higher mortality rate was observed in 
non-smoker than current smokers, although this was statistically 
insignificant, possibly due to a higher mean age in non-smokers 
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(58.08 ± 10.47 years) than in current smokers (56.63 ± 12.22 
years), together with the non-smoker group having more risk 
factors like diabetes mellitus and hypertension. Giannitsis et 
al[27]. who studied 140 patients with STEMI showed that high-
er levels of cTnT measured on admission were associated with 
poorer epicardial and tissue perfusion after PPCI. Velders et 
al[28]. showed that hs-cTnT, N-terminal probrain natriuretic pep-
tide, extent of angiographic CAD, and growth differentiation 
factor-15 measured on admission predict the occurrence of sub-
sequent cardiovascular death or MI compared with clinical in-
formation alone in STEMI patients reperfused by PPCI. Wang et 
al.[29] studied 173 STEMI patients undergoing PPCI and reported 
that the incidence of MACE (death, myocardial infarction and 
revascularization) at 30 days and 1 year were 10% and 18% re-
spectively. They concluded that hs-cTnT measured on admission 
in patients with STEMI was strongly associated with 30 day and 
1 year rates of major adverse events after PPCI[29]. 
 Other outcomes of myocardial infarction were worse 
in the non-survived group than survived, such as heart failure, 
other complications (like reinfarction, stent thrombosis, stroke, 
renal impairment, and upper gastrointestinal tract bleeding), 
higher  rates of recurrent chest pain, more readmissions, and 
increased need for further revascularizations. Although few 
patients developed these complications possibly due to small 
sample size, these were in agreement with the results of other 
studies that also showed higher rates of  heart failure[30-31], renal 
failure[29,31], reinfarction and revascularizations[29] that were as-
sociated with higher baseline hs-cTnT levels, possibly reflecting 
an increase in the extent of myocardial necrosis and end-organ 
damage. According to these data there is a close association be-
tween hs-cTnT with baseline cardiovascular risk and the extent 
of myocardial damage in patients with STEMI and subsequent 
mortality. In the present study higher hs-cTnT was associated 
with higher mortality possibly due to higher risk profile like age, 
DM and multivessel coronary artery lesions.
Limitations
Contact with a lot of patients was lost during follow up. This led 
to a reduced sample size.
 In this study the effect of different medications used 
following PCI was not investigated. This could have had a con-
founding effect. In addition dyslipidaemia was not measured in 
this study, which could also have had a confounding effect. Pa-
tients in group B were more likely to be hypertensive; however, 
no further analysis was carried out regarding the relationship be-
tween hypertension and hs-cTnT. 
 This is a small observational cohort study carried out in 
a single center; therefore the wider application of these results 
may be limited.
Conclusion
High initial hs-cTnT on admission is associated with a greater 
risk of mortality and morbidity at 2-year follow up in patients 
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